The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Will frontline DLBCL treatment become subtype-specific rather than a one-regimen-fits-all approach?
In this video, Umberto Vitolo, MD, Candiolo Cancer Institute (FPO-IRCCS), Turin, Italy, discusses whether frontline treatment for diffuse large B-cell lymphoma (DLBCL) may eventually become subtype-specific rather than relying on a “one-regimen-fits-all” approach. Prof. Vitolo notes that although multiple studies have explored subtype-targeted strategies, many treatments appear to be effective across both major subtypes. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is another good question. Of course, we know that there are several subtypes of diffuse large B-cell lymphoma. However, so far we did many attempts in many studies to target different subtypes without success, honestly. And in the tafa-len, plus R-CHOP study, it’s interesting to note that the advantage was observed either in the GCB and ABC subtypes. In some ways, it means that the clinician can just skip this classification because they know they have another treatment that is working in both subtypes...
This is another good question. Of course, we know that there are several subtypes of diffuse large B-cell lymphoma. However, so far we did many attempts in many studies to target different subtypes without success, honestly. And in the tafa-len, plus R-CHOP study, it’s interesting to note that the advantage was observed either in the GCB and ABC subtypes. In some ways, it means that the clinician can just skip this classification because they know they have another treatment that is working in both subtypes. And nevertheless, I think that it’s important to continue to recognize the subtypes of the DLBCL in order to find out some more specific targeting agents that can have benefits for patients with different types.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
